[1]
|
Schade, D.S., Cavanaugh, B., Ramo, B. and Eaton, R.P. (2016) The Application of the LDL Principle. World Journal of Cardiovascular Diseases, 6, 109-125.
https://doi.org/10.4236/wjcd.2016.65012
|
[2]
|
Tota-Maharaj, R., Blaha, M.J., McEvoy, J.W., Blumenthal, R.S., Muse, E.D., Budoff, M.J., et al. (2012) Coronary Artery Calcium for the Prediction of Mortality in Young Adults <45 Years Old and Elderly Adults >75 Years Old. European Heart Journal, 33, 2955-2962. https://doi.org/10.1093/eurheartj/ehs230
|
[3]
|
Greenland, P., Knoll, M.D., Stamler, J., Neaton, J.D., Dyer, A.R., Garside, D.B., et al. (2003) Major Risk Factors as Antecedents of Fatal and Nonfatal Coronary Heart Disease Events. JAMA, 290, 891-897. https://doi.org/10.1001/jama.290.7.891
|
[4]
|
Nasir, K., Rubin, J., Blaha, M.J., Shaw, L.J., Blankstein, R., Rivera, J.J., et al. (2012) Interplay of Coronary Artery Calcification and Traditional Risk Factors for the Prediction of All-Cause Mortality in Asymptomatic Individuals. Circulation: Cardiovascular Imaging, 5, 467-473. https://doi.org/10.1161/CIRCIMAGING.111.964528
|
[5]
|
Silverman, M.G., Ference, B.A., Im, K., Wiviott, S.D., Giugliano, R.P., Grundy, S.M., et al. (2016) Association between Lowering LDL-C and Cardiovascular Risk Reduction among Different Therapeutic Interventions: A Systematic Review and Meta-Analysis. JAMA, 316, 1289-1297. https://doi.org/10.1001/jama.2016.13985
|
[6]
|
Cholesterol Treatment Trialists’ (CTT) Collaboration. (2010) Efficacy and Safety of More Intensive Lowering of LDL Cholesterol: A Meta-Analysis of Data from 170,000 Participants in 26 Randomised Trials. Lancet, 376, 1670-1681.
https://doi.org/10.1016/S0140-6736(10)61350-5
|
[7]
|
Cholesterol Treatment Trialists’ (CTT) Collaborators, Mihaylova, B., Emberson, J., Blackwell, L., Keech, A., Simes, J., et al. (2012) The Effects of Lowering LDL Cholesterol with Statin Therapy in People at Low Risk of Vascular Disease: Meta-Analysis of Individual Data from 27 Randomised Trials. Lancet, 380, 581-590.
https://doi.org/10.1016/S0140-6736(12)60367-5
|
[8]
|
Gao, W.Q., Feng, Q.Z., Li, Y.F., Li, Y.X., Huang, Y., Chen, Y.M., et al. (2014) Systematic Study of the Effects of Lowering Low-Density Lipoprotein-Cholesterol on Regression of Coronary Atherosclerotic Plaques Using Intravascular Ultrasound. BMC Cardiovascular Disorders, 14, 60-78. https://doi.org/10.1186/1471-2261-14-60
|
[9]
|
Nakamura, T., Obata, J.E., Kitta, Y., Takano, H., Kobayashi, T., Fujioka, D., et al. (2008) Rapid Stabilization of Vulnerable Carotid Plaque within 1 Month of Pitavastatin Treatment in Patients with Acute Coronary Syndrome. Journal of Cardiovascular Pharmacology, 51, 365-371. https://doi.org/10.1097/FJC.0b013e318165dcad
|
[10]
|
Takarada, S., Imanishi, T., Kubo, T., Tanimoto, T., Kitabata, H., Nakamura, N., et al. (2009) Effect of Statin Therapy on Coronary Fibrous-Cap Thickness in Patients with Acute Coronary Syndrome: Assessment by Optical Coherence Tomography Study. Atherosclerosis, 202, 491-497.
https://doi.org/10.1016/j.atherosclerosis.2008.05.014
|
[11]
|
Libby, P. and Theroux, P. (2005) Pathophysiology of Coronary Artery Disease. Circulation, 111, 3481-3488. https://doi.org/10.1161/CIRCULATIONAHA.105.537878
|
[12]
|
Kubo, T., Imanishi, T., Takarada, S., Kuroi, A., Ueno, S., Yamano, T., et al. (2007) Assessment of Culprit Lesion Morphology in Acute Myocardial Infarction: Ability of Optical Coherence Tomography Compared with Intravascular Ultrasound and Coronary Angioscopy. Journal of the American College of Cardiology, 50, 933-939.
https://doi.org/10.1016/j.jacc.2007.04.082
|
[13]
|
van der Wal, A.C., Becker, A.E., van der Loos, C.M. and Das, P.K. (1994) Site of Intimal Rupture or Erosion of Thrombosed Coronary Atherosclerotic Plaques Is Characterized by an Inflammatory Process Irrespective of the Dominant Plaque Morphology. Circulation, 89, 36-44. https://doi.org/10.1161/01.CIR.89.1.36
|
[14]
|
Nicholls, S.J., Ballantyne, C.M., Barter, P.J., Chapman, J., Erbel, R.M., Libby, P., et al. (2011) Effect of Two Intensive Statin Regimens on Progression of Coronary Disease. The New England Journal of Medicine, 365, 2078-2087.
https://doi.org/10.1056/NEJMoa1110874
|
[15]
|
Nissen, S.E., Nicholls, S.J., Sipahi, I., Libby, P., Raichlen, J.S., Ballantyne, C.M., et al. (2006) Effect of Very High-Intensity Statin Therapy on Regression of Coronary Atherosclerosis—The ASTEROID Trial. JAMA, 295, 1556-1565.
https://doi.org/10.1001/jama.295.13.jpc60002
|
[16]
|
Sabatine, M.S., Giugliano, R.P., Keech, A.C., Honarpour, N., Wiviott, S.D., Murphy, S.A., et al. (2017) Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. The New England Journal of Medicine, 376, 1713-1722.
https://doi.org/10.1056/NEJMoa1615664
|
[17]
|
The HPS3/TIMI55-REVEAL Collaborative Group (2017) Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. The New England Journal of Medicine, 377, 1217-1227. https://doi.org/10.1056/NEJMoa1706444
|
[18]
|
Ridker, P.M., Everett, B.M., Thuren, T., MacFadyen, J.G., Chang, W.H., Ballantyne, C., et al. (2017) Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. The New England Journal of Medicine, 377, 1119-1131.
https://doi.org/10.1056/NEJMoa1707914
|
[19]
|
Davies, M.J., Richardson, P.D., Woolf, N., Katz, D.R. and Mann, J. (1993) Risk of Thrombosis in Human Atherosclerotic Plaques: Role of Extracellular Lipid, Macrophage, and Smooth Muscle Cell Content. British Heart Journal, 69, 377-381.
https://doi.org/10.1136/hrt.69.5.377
|
[20]
|
Leber, A.W., Knez, A., White, C.W., Becker, A., von Ziegler, F., Muehling, O., et al. (2003) Composition of Coronary Atherosclerotic Plaques in Patients with Acute Myocardial Infarction and Stable Angina Pectoris Determined by Contrast-Enhanced Multislice Computed Tomography. American Journal of Cardiology, 91, 714-718. https://doi.org/10.1016/S0002-9149(02)03411-2
|
[21]
|
Hansson, G.K. (2005) Inflammation, Atherosclerosis, and Coronary Artery Disease. The New England Journal of Medicine, 352, 1685-1695.
https://doi.org/10.1056/NEJMra043430
|
[22]
|
Libby, P. (2002) Inflammation in Atherosclerosis. Nature, 420, 868-874.
https://doi.org/10.1038/nature01323
|
[23]
|
Puri, R., Nicholls, S.J., Shao, M., Kataoka, Y., Uno, K., Kapadia, S.R., et al. (2015) Impact of Statins on Serial Coronary Calcification during Atheroma Progression and Regression. Journal of the American College of Cardiology, 65, 1273-1282.
https://doi.org/10.1016/j.jacc.2015.01.036
|
[24]
|
Ross, R. (1999) Atherosclerosis—An Inflammatory Disease. The New England Journal of Medicine, 340, 115-126. https://doi.org/10.1056/NEJM199901143400207
|
[25]
|
Ridker, P.M., Rifai, N., Pfeffer, M.A., Sacks, F.M., Moye, L.A., Goldman, S., et al. (1998) Inflammation, Pravastatin, and the Risk of Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels. Circulation, 98, 839-844.
https://doi.org/10.1161/01.CIR.98.9.839
|
[26]
|
Ridker, P.M., Cannon, C.P., Morrow, D., Rifai, N., Rose, L.M., McCabe, C.H., et al. (2005) C-Reactive Protein Levels and Outcomes after Statin Therapy. The New England Journal of Medicine, 352, 20-28. https://doi.org/10.1056/NEJMoa042378
|
[27]
|
Ridker, P.M. (2001) High-Sensitivity C-Reactive Protein: Potential Adjunct for Global Risk Assessment in the Primary Preventon of Cardiovascular Disease. Circulation, 103, 1813-1818. https://doi.org/10.1161/01.CIR.103.13.1813
|
[28]
|
Davidson, M.H. (2005) Reducing Residual Risk for Patients on Statin Therapy: The Potential Role of Combination Therapy. Davidson Reducing Residual Risk for Patients on Statin Therapy. American Journal of Cardiology, 96, 3K-13K.
https://doi.org/10.1016/j.amjcard.2005.08.002
|
[29]
|
Baigent, C., Keech, A., Kearney, P.M., Blackwell, L., Buck, G., Pollicino, C., et al. (2005) Efficacy and Safety of Cholesterol-Lowering Treatment: Prospective Meta-Analysis of Data from 90,056 Participants in 14 Randomised Trials of Statins. The Lancet, 366, 1267-1278. https://doi.org/10.1016/S0140-6736(05)67394-1
|
[30]
|
Cannon, C.P., Blazing, M.A., Giugliano, R.P., McCagg, A., White, J.A., Theroux, P., et al. (2015) Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. The New England Journal of Medicine, 372, 2387-2397.
https://doi.org/10.1056/NEJMoa1410489
|
[31]
|
Ray, K.K., Cannon, C.P., McCabe, C.H., Cairns, R., Tonkin, A.M., Sacks, F.M., et al. (2005) Early and Late Benefits of High-Dose Atorvastatin in Patients with Acute Coronary Syndromes: Results from the PROVE IT-TIMI 22 Trial. Journal of the American College of Cardiology, 46, 1405-1410.
https://doi.org/10.1016/j.jacc.2005.03.077
|
[32]
|
Everett, B.M., Smith, R.J. and Hiatt, W.R. (2015) Reducing LDL with PCSK9 Inhibitors—The Clinical Benefit of Lipid Drugs. The New England Journal of Medicine, 373, 1588-1591. https://doi.org/10.1056/NEJMp1508120
|
[33]
|
Taylor, A.J., Bindeman, J., Feuerstein, I., Le, T., Bauer, K., Byrd, C., et al. (2008) Community-Based Provision of Statin and Aspirin after the Detection of Coronary Artery Calcium within a Community-Based Screening Cohort. Journal of the American College of Cardiology, 51, 1337-1341.
https://doi.org/10.1016/j.jacc.2007.11.069
|
[34]
|
Campbell, C.L., Smyth, S., Montalescot, G. and Steinhubl, S.R. (2007) Aspirin Dose for the Prevention of Cardiovascular Disease: A Systematic Review. JAMA, 297, 2018-2024. https://doi.org/10.1001/jama.297.18.2018
|
[35]
|
Ridker, P.M., Cushman, M., Stampfer, M.J., Tracy, R.P. and Hennekens, C. (1997) Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy Men. The New England Journal of Medicine, 336, 973-979.
https://doi.org/10.1056/NEJM199704033361401
|
[36]
|
Hu, F.B. and Willett, W.C. (2002) Optimal Diets for Prevention of Coronary Heart Disease. JAMA, 288, 2569-2578. https://doi.org/10.1001/jama.288.20.2569
|
[37]
|
Blair, S.N., Kohl, H.W. III, Barlow, C.E., Paffenbarger Jr., R.S., Gibbons, L.W. and Macera, C.A. (1995) Changes in Physical Fitness and All-Cause Mortality: A Prospective Study of Healthy and Unhealthy Men. JAMA, 273, 1093-1098.
https://doi.org/10.1001/jama.1995.03520380029031
|
[38]
|
Myers, J., Prakash, M., Froelicher, V., Do, D., Partington, S. and Atwood, J.E. (2002) Exercise Capacity and Mortality among Men Referred for Exercise Testing. The New England Journal of Medicine, 346, 793-801.
https://doi.org/10.1056/NEJMoa011858
|
[39]
|
Schwartz, G.G., Olsson, A.G., Ezekowitz, M.D., Ganz, P., Oliver, M.F., Waters, D., et al. (2001) Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary Syndromes—The MIRACL Study: A Randomized Controlled Trial. JAMA, 285, 1711-1718. https://doi.org/10.1001/jama.285.13.1711
|
[40]
|
Mehta, S.R. (2009) Aspirin for Prevention and Treatment of Cardiovascular Disease. Annals of Internal Medicine, 150, 414-416.
https://doi.org/10.7326/0003-4819-150-6-200903170-00011
|
[41]
|
Couzin-Frankel, J. (2016) Lipid Biology. Why High Good Cholesterol Can Be Bad News. Science, 351, 1126. https://doi.org/10.1126/science.351.6278.1126
|